Target Cell Populations of Human Immunodeficiency Virus Type 1 in Peripheral Blood Lymphocytes with Different Chemokine Receptors at Various Stages of Disease Progression
暂无分享,去创建一个
[1] Q. Sattentau,et al. Selective HIV-1-induced downmodulation of CD4 and coreceptors , 2000, Archives of Virology.
[2] S. Suwanagool,et al. Increase in activated CD4+ lymphocytes with CCR5 and CXCR4 in HIV type 1-infected persons. , 1999, AIDS research and human retroviruses.
[3] G. Simmons,et al. Expanded Tropism of Primary Human Immunodeficiency Virus Type 1 R5 Strains to CD4+ T-Cell Lines Determined by the Capacity To Exploit Low Concentrations of CCR5 , 1999, Journal of Virology.
[4] Anthony S. Fauci,et al. Both Memory and CD45RA+/CD62L+ Naive CD4+ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals , 1999, Journal of Virology.
[5] H. Schuitemaker,et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. , 1999, The Journal of infectious diseases.
[6] R. Lal,et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. , 1998, Virology.
[7] H. Schuitemaker,et al. Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV infection and prognostic value of SI phenotype for survival after aids diagnoses , 1997 .
[8] C. Mackay,et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[9] O. Ramilo,et al. Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Weiss,et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry , 1996, Journal of virology.
[11] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[12] L. Ratner,et al. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells , 1996, Journal of virology.
[13] J. Levy,et al. Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation , 1995, Journal of virology.
[14] C. Beyrer,et al. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand , 1995, Journal of virology.
[15] H. Schuitemaker,et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. , 1993, Science.
[16] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[17] J. Yourno,et al. A novel polymerase chain reaction method for detection of human immunodeficiency virus in dried blood spots on filter paper , 1992, Journal of clinical microbiology.
[18] M. Giacca,et al. Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction , 1992, Journal of clinical microbiology.
[19] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[20] Huisman,et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.
[21] M. Sanders,et al. Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. , 1988, Immunology today.